Crescent Biopharma, Inc. (CBIO)
NASDAQ: CBIO · Real-Time Price · USD
13.07
+0.08 (0.62%)
At close: Dec 5, 2025, 4:00 PM EST
12.60
-0.47 (-3.60%)
After-hours: Dec 5, 2025, 7:42 PM EST
Crescent Biopharma Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Crescent Biopharma stock have an average target of 25.6, with a low estimate of 22 and a high estimate of 28. The average target predicts an increase of 95.87% from the current stock price of 13.07.
Analyst Consensus: Strong Buy
* Price targets were last updated on Aug 27, 2025.
Analyst Ratings
The average analyst rating for Crescent Biopharma stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 3 | 3 | 3 | 3 | 3 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $25 | Strong Buy | Reiterates | $25 | +91.28% | Aug 27, 2025 |
| Jefferies | Jefferies | Strong Buy Initiates $26 | Strong Buy | Initiates | $26 | +98.93% | Aug 25, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $25 | Strong Buy | Initiates | $25 | +91.28% | Aug 11, 2025 |
| Wedbush | Wedbush | Buy Initiates $27 | Buy | Initiates | $27 | +106.58% | Jul 14, 2025 |
| Stifel | Stifel | Strong Buy Initiates $28 | Strong Buy | Initiates | $28 | +114.23% | Jun 25, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-7.80
from -13.45
EPS Next Year
-5.75
from -7.80
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -8.03 | -3.39 | ||||
| Avg | -7.80 | -5.75 | ||||
| Low | -7.50 | -10.30 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.